The validity of giving adjuvant capecitabine after standard anthracycline and/or taxanes based neo-/adjuvant chemotherapy in early triple-negative breast cancer patients: An Egyptian prospective multicentric phase III trial

Background: Triple-negative breast cancer (TNBC) is considered an aggressive breast cancer subtype despite giving standard therapies, these patients have high metastatic and relapse rates in addition to short survival. Therefore, we conducted this trial to study the validity of giving adjuvant Capec...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Marwa Abdelgawad, loay Gertalla, Alia Attia, Ahmed Hefni, lobna Abdelaziz
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	The Egyptian Association for Cancer Research (EACR) 2022-06-01
Edice:	Egyptian Journal of Cancer and Biomedical Research
Témata:	Triple-Negative Breast Cancer Capecitabine Adjuvant Chemotherapy survival safety profile
On-line přístup:	https://jcbr.journals.ekb.eg/article_253126_e9d04975910274458f197ac6fbcb3f4a.pdf
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!